SOLICITATION NOTICE
Q -- A hospital-based case-control study of lymphoma in Asia (AsiaLymph): Tianjin
- Notice Date
- 8/9/2011
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-110149-TG
- Archive Date
- 9/7/2011
- Point of Contact
- Terry Galloway, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
gallowaytl@mail.nih.gov, cr214i@nih.gov
(gallowaytl@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Room 6074, Rockville, MD, 20852, UNITED STATES Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Occupational and Environmental Epidemiology Branch (OEEB) plans to procure on a sole source basis coordination services for the Tianjin study centers of the AsiaLymph Study from Tianjin Medical University Cancer Institute and Hospital Huan-Hu-Xi Road, Ti-yuan-Bei, Hexi District, Tianjin, 300060 CHINA. The services herein are being procured in accordance with the simplified acquisition procedures as authorized by FAR Part 13.106-1 (b)(1). The North American Industry Classification System code is 621511 and the business size standard is $13.5 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance shall be for twelve (12) months from date of award. The contribution of environmental, occupational and genetic factors to lymphoma has generated a series of novel, cutting edge findings in studies of Caucasians. To optimize the ability to build on and clarify these findings, it is necessary to investigate populations that differ from Caucasians in both exposure patterns and underlying genetic structure. Thus, a hospital-based case-control study of lymphoma in Eastern Asia (i.e., AsiaLymph) of cases and controls to be enrolled over a three-year period will be conducted. The major postulated risk factors for evaluation in this study are chemical exposures (i.e., organochlorines, trichloroethylene and benzene), genetic susceptibility, and infectious agents. A particularly noteworthy aspect of AsiaLymph is central pathology review with immunophenotyping, which will enable accurate analysis of findings by molecular and histologic subtypes. AsiaLymph should confirm and extend previous findings, and yield novel insights into the causes of lymphoma in both Asia and the West. The major postulated risk factors for evaluation in this study are chemical exposures such as organochlorines, trichloroethylene and benzene. To properly assess these exposures among lymphoma cases and controls, accurate and historical data assessing organochlorines, trichloroethylene and benzene levels in the various workplaces in critical. The Tianjin Medical University Cancer Institute and Hospital system is a premier lymphoma hospital system in eastern China, with ample lymphoma cases and controls necessary for the AsiaLymph protocol. Researchers at the Tianjin Medical University Cancer Institute and Hospital System have the necessary historical data assessing various workplace chemical exposures. This data is comparable to similar data from the Hong Kong and Taiwan centers, thus allowing for the necessary pooling of data across all of AsiaLymph. The Tianjin Medical University Cancer Institute and Hospital system is the only known hospital in eastern China that can fulfill the requirements of this procurement. Further, a study coordinator is needed to manage all aspects of the AsiaLymph study for the participating hospitals in Tianjin, China. To successfully manage these hospitals, the investigator must have efficiently and productively worked with clinicians, pathologists, epidemiologists, and hospital administrators within these hospital systems. Upon discussions with collaborators throughout mainland China and international experts at scientific meetings, Dr. Chen was identified as having previously collaborated on epidemiological initiatives with these hospital systems. Dr. Chen has extensive experience conducting epidemiological studies in Tianjin. As such, the Tianjin Medical University Cancer Institute and Hospital system is the only candidate to fulfill the tasks of this procurement. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 11:00 AM EST, on August 23, 2011. For further information, please contact Terry Galloway, Contract Specialist via electronic mail at gallowaytl@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed or emailed capability statements will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Reference: NCI-110149-TG on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-110149-TG/listing.html)
- Record
- SN02527355-W 20110811/110809235705-4169aae6c90f1b0a86a470b3990b0874 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |